Best India Stocks To Buy Right Now


It has been one month since the BPC cartel breakup announcement on July 29-30 rocked the world’s potash suppliers. There have been many articles, varied takes and analysis done on specific stocks and the entire industry, from the macro implications and ramifications on down. Recently, news broke on an Indian government program being enacted to subsidize grains for farmers and the poor. That will likely have an affect on potash, but the news could be favorable or unfavorable. Investors won’t know until the subsidy plan is implemented and has some ripples on the limping Indian economy. Other news on India’s demands on the Uralkali company regarding lower potash prices also came to light on August 16th.


I have been following the various media, as well as reading all of the SA and related takes on the updates on this still uncertain tale as it unwinds and plays out. We are not near the finish line. In fact we are still inside the dark tunnel, figuratively. At least there is no discernible sound of a locomotive emerging from the pitch black (as of yet).

Best India Stocks To Buy Right Now: Infosys Technologies Limited(INFY)

Infosys Ltd. provides information technology (IT) and consulting services worldwide. It offers IT services, such as application, architecture, independent validation and testing, information management, infrastructure, packaged application, SOA, systems integration, and knowledge services; product engineering services, manufacturing process and plant solutions, and product lifecycle management services; and consulting services in the areas of information and technology strategies, product innovation, next generation commerce, process excellence, and learning and complex change. The company also provides business process outsourcing solutions in the areas of business platforms, customer service outsourcing, finance and accounting, human resources outsourcing, legal services, sales and fulfillment, and sourcing and procurement outsourcing. In addition, it offers collaborative analytics solutions; digital consumer platform; Finacle universal banking solution; iProwe, a Web ac cessibility assessment product; mConnect, a real-time enterprise middleware; and research and analytical support services. Further, the company offers unified communications and collaboration solution that streamlines business processes between employees, customers, and suppliers; iTransform that helps healthcare organizations accelerate transition to new platforms; and supply chain visibility and collaboration product suite. It serves aerospace and defense, airlines, automotive, banking, capital markets, communication services, consumer packaged goods, manufacturing, education, energy, healthcare, high technology, hospitality and leisure, insurance, life sciences, logistics and distribution, publishing, resources, utilities, and retail industries. Infosys Ltd. has a strategic partnership with Alstom SA. The company was formerly known as Infosys Technologies Limited and changed its name to Infosys Ltd. on June 16, 2011. Infosys Ltd. was founded in 1981 and is headquartered i n Bengaluru, India.


Advisors’ Opinion:

  • [By Dan Caplinger]

    Overall, the most popular emerging market ETFs experienced much sharper declines than the less-than-1% drop the Dow posted this week. Vanguard Emerging Markets (NYSEMKT: VWO  ) and iShares Emerging Markets (NYSEMKT: EEM  ) were both down just under 3% for the week. But when you drill down to look for particular culprits in the emerging markets, you don’t have to look very far to find that it was generally a broad-based decline:

    In China, more concerns about a slowdown in the manufacturing industry put pressure on stocks. The Shanghai index didn’t move much, but one key ETF tracking the Chinese market sank nearly 4% in response to the news, largely on weakness in telecom giant China Mobile (NYSE: CHL  ) , which plays a commanding role in many emerging market-focused ETFs.
    Indian stocks suffered from some of the same macroeconomic issues, with the Bombay market’s index down about 3% and ETF tracking the market falling 4% to 5%. The Indian finance minister responded to the decline, which many blamed on Fed Chair Ben Bernanke’s comments, by saying, “We think that Bernanke’s statement has been misunderstood or misinterpreted.” Yet that didn’t seem to appease investors in outward-directed industries like Infosys (NYSE: INFY  ) , whose IT offerings require health activity levels not just in India but in the U.S. and other customer-heavy countries as well.
    Stocks in Mexico suffered declines of almost 5%, retracing some ground after an extraordinarily strong stretch of gains on optimism about the country’s ability to reinvigorate its economy beyond its core reliance on petroleum and to resolve ongoing conflicts with drug cartels.


    But there were some relatively bright spots in other emerging markets. Brazilian stocks were actually up a bit on the week, as the nation found itself better insulated from all the happenings in Asia related to China and Japan. Russian stocks also remained relatively stable,

  • [By Robert Martin]

    Infosys (INFY), Housing Development Finance and Reliance Industries LTD are the top three holdings, with weightings between 8% and 10.5%. Of course, just about any India ETF will have a heavy allocation to Infosys and Reliance. However, INDA dedicates a lower percentage to energy than some of the alternatives, and instead leans more on IT and consumer spending.

  • [By Brian Stoffel]

    That helps explain why Accenture and IBM,the industry’s two biggest players, have been able to gobble up so much market share. But there’s a second tier of technology-consultants — in terms of sheer size — as well. That’s where Cognizant, as well as its main competition –Infosys (NYSE: INFY  ) and Wipro (NYSE: WIT  ) — come in to play.

  • [By Aaron Smith]

    The government accused software developer Infosys (INFY) of using workers with B-1 visas, which only allow temporary entry into the U.S. for business purposes, to perform skilled labor jobs.

Best India Stocks To Buy Right Now: Tata Motors Ltd(TTM)


Tata Motors Limited, an automobile company, engages in the manufacture and sale of commercial and passenger vehicles primarily in India. The company offers cars, utility vehicles, trucks, buses and coaches, and defense vehicles, as well as develops electric and hybrid vehicles for personal and public transportation. It also involves in distributing and marketing cars; and financing the vehicles sold by the company. In addition, the company engages in the provision of engineering and automotive solutions, as well as machine tools and factory automation solutions; construction equipment manufacturing; automotive vehicle components manufacturing and supply chain activities; tooling and plastic and electronic components for automotive and computer applications; and automotive retailing and service operations. It offers its products and services through its dealership, sales, services, and spare parts network. The company also markets its commercial and passenger vehicles in Eu rope, Africa, the Middle East, South East Asia, South Asia, and South America. The company was formerly known as Tata Engineering and Locomotive Company Limited and changed its name to Tata Motors Limited in July 2003. Tata Motors Limited was founded in 1945 and is based in Mumbai, India.


Advisors’ Opinion:

  • [By Justin Loiseau]

    2. Gimme those car keys
    Sniff … they grow up so fast. Before we know it, little Georgie’s going to be ready to sit his royal tuckus in the driver seat. Tata Motors (NYSE: TTM  ) offers a flashback to the days of British colonialism, although this time it’s India with the ownership. Although the South Asian automaker is most famous for its Tata Nano, the world’s cheapest car, Prince George would probably have his eyes set on Tata’s Jaguar Land Rover subsidiary.

  • [By David Kerr]

    Using the conventional P/E method, if we subtract the $39 billion in cash that Oracle has from the $155 billion market cap, we see that the companys operations can be purchased for $116 billion. Because Oracle has a net income of $11 billion (TTM), the company is actually trading at a P/E of 10.54 as opposed to the current 14.46. Oracle also has an estimated Forward P/E (1 year) of 10.65.

  • [By James Well]

    Pfizers Net Income Growth Is Increasing Leading to Increase in Its Operating Margins


    Net incomes and operating margins of a company give some insights into its financial health. Pfizers net income growth has accelerated this year. In fact, when compared with its direct competitors like Merck, Novartis, and Sanofi, the rate of increase of net income growth trailing twelve months (TTM) is greatest at Pfizer with $10.68 billion followed by Novartis with $9.37 billion while Merck and Sanofi lagged behind with $4.53 billion and $4.05 billion respectively. Really, rather than increasing, there has been a decrease in Mercks and Sanofis net incomes this year which should be a source of concern for investors. A healthy operating margin shows that a company is earning more per dollar of sales and, hence, able to pay for its fixed costs including interest on debt.

  • [By Bruce Kennedy]

    Very mixed news has been released lately onTata Motors (NYSE: TTM).

    The Mumbai-based company reported a 71 percent jump in net profit to $566 million (35.42 billion rupees) for its fiscal second quarter ending September 30, compared to the same time period a year earlier. Revenue rose 31 percent, beating analysts’ expectations.

Top 5 Biotech Companies For 2014: Stewart Information Services Corporation(STC)


Stewart Information Services Corporation provides title insurance and related information services required for settlement by the real estate and mortgage industries. It operates in two segments, Title Insurance-Related Services and Real Estate Information. The Title Insurance-Related Services segment offers services that include searching for and examining documents, such as deeds, mortgages, wills, divorce decrees, court judgments, liens, paving assessments, and tax records, as well as provides titles insurance for residential and commercial properties, undeveloped acreage, farms, ranches, and water rights. This segment serves attorneys, builders, developers, home buyers and home sellers, lenders, and real estate brokers. The Real Estate Information segment offers products and services, which primarily include lender services, title technology, foreign and domestic government services, mapping, title information, Internal Revenue Code Section 1031 tax-deferred property e xchanges, pre-employment services, and online filing and transaction management. Its customers include mortgage lenders and servicers, mortgage brokers, mortgage investors, government entities, commercial and residential real estate agents, land developers, builders, title insurance agencies, and others interested in obtaining property information, as well as accountants, attorneys, investors, and employers. The company has operations primarily in the United States, Canada, the United Kingdom, central Europe, Mexico, central America, and Australia. Stewart Information Services Corporation was founded in 1893 and is based in Houston, Texas.


Advisors’ Opinion:

  • [By Ben Levisohn]

    Tower Group has dropped 12% to $3.88 today at 11:39 a.m., while Stewart Information Services (STC) has dipped 0.1% to $31.16, theNavigators Group(NAVG) has fallen 1.4% to $54.78 and HCI Group(HCI) has gained 1% to $38.16.

  • [By Ben Levisohn]

    Tower Group has dropped 40% to $4.43 today, and some other small insurers are also getting dinged this morning. HCI Group (HCI) has fallen 1.8% to $39.36, Stewart Information Services (STC) has declined 0.7% to $31.36 and the Navigators Group (NAVG) has ticked down 0.4% to $56.10.

  • [By James Fink]

    My housing pick is Houston-based Stewart Information Services (STC), a 120-year-old real estate business founded in 1893, that is still owned and managed by the founding family.

Best India Stocks To Buy Right Now: Dr. Reddy’s Laboratories Ltd(RDY)

Dr. Reddy?s Laboratories Limited, together with its subsidiaries, operates as a pharmaceutical company. It produces finished dosage forms, active pharmaceutical ingredients and intermediates, and biotechnology products. The company also conducts research in the areas of cancer, diabetes, cardiovascular, inflammation, and bacterial infection. In addition, it involves in the contract manufacture generic prescription and over-the-counter products for branded and generic companies in the United States. The company primarily focuses on therapeutic categories of cardiovascular, diabetes management, gastro-intestinal, and pain management. It markets its products in India, the United States, Europe, and the Russian Federation. The company has a co-development and commercialization agreement with Rheoscience A/S for the development and commercialization of Balaglitazone/DRF 2593, a partial PPAR-gamma agonist for the treatment of type 2 diabetes; an agreement with ClinTec Internatio nal for the development of an anti-cancer compound, DRF 1042; collaboration with the National Cancer Institute in Maryland; and an agreement with Argenta Discovery Limited for the joint development and commercialization of a novel approach to the treatment of chronic obstructive pulmonary disease. It also has an agreement with 7TM Pharma for drug discovery collaboration on selected drug targets; and an agreement with GlaxoSmithKline plc to develop and market pharmaceuticals for the treatment of cardiovascular disease, diabetes, oncology, gastroenterology, and pain management. Dr. Reddy?s Laboratories Limited was founded in 1984 and is headquartered in Hyderabad, India.


Advisors’ Opinion:

  • [By Ben Levisohn]

    Teva has dropped 7.7% to $37.85 today at 3:23 p.m. but doesn’t seem to be spreading though the generic drug space. Taro Pharmaceuticals (TARO) ha gained 1.1% to $79, while Actavis (ACT) has gained 1.2% to $156.25 and Dr. Reddy’s Laboratories (RDY) has advanced 1% to $40.24. Mylan (MYL) has dropped 0.7% to $38.40.

  • [By Dan Carroll]

    The company’s generic drug segment should also help push emerging market sales. Abbott markets generic pharmaceuticals outside the U.S. only, and while the division isn’t growth-oriented — sales actually fell around 2% for the quarter — it provides an entry for the company to push into lucrative new markets such as India, where generics make up the large majority of the country’s retail market. The company will face tougher competition in this industry, however: Firms such as India-based Dr. Reddy’s (NYSE: RDY  ) have also pushed hard into emerging markets lately, and Dr. Reddy’s in particular should benefit from its being headquartered in one of the industry’s top locales.

  • [By Seth Jayson]

    Dr. Reddy’s Laboratories (NYSE: RDY  ) reported earnings on May 14. Here are the numbers you need to know.

    The 10-second takeaway
    For the quarter ended March 31 (Q4), Dr. Reddy’s Laboratories beat expectations on revenues and beat expectations on earnings per share.

  • [By Rich Duprey]

    Following FDA approval of its abbreviated new drug application, or ANDA,Dr. Reddy’s Laboratories (NYSE: RDY  ) announced today that it launched its lamotrigine extended-release tablets, the generic version of GlaxoSmithKline’s Lamictal.